CTLA4 and hepatocellular carcinoma: Another study reported lower baseline fecal calprotectin levels in patients with hepatocellular carcinoma (HCC) who clinically benefited from the ICI therapy (anti-CTLA-4 and/or anti-PD-L1 therapy) in comparison to those with PD [24].